drugset
drugset / Trial / NCT05585034

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

NCT05585034 ↗

Phase 1 Completed 60 enrolled Xencor, Inc.
NaSequentialOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with selected advanced solid tumors and to identify the minimum safe and biologically effective/recommended dose (RD) and schedule for XmAb808.

Timeline

Start
2022-12-14
Primary completion
2025-05-20
Completion
2025-05-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Pembrolizumab Monoclonal antibody — —
Subject XmAb808 Monoclonal antibody — Intravenous

Indications

castration-resistant prostate carcinoma clear cell renal carcinoma colorectal cancer head and neck squamous cell carcinoma malignant epithelial tumor of ovary melanoma non-small cell lung carcinoma triple-negative breast carcinoma urothelial carcinoma